TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28302543
Drug: Pidotimod (PDT)
Normalized name: pidotimod
DrugBank: Pidotimod (DB11364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pidotimod (PDT) 800mg, 2 daily doses
Study: 28302543
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg b.i.d. alone
Study: 21701222
Drug: Oral erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral erythromycin ethylsuccinate at a dose of 50 mg/kg/day for 10 days
Study: 2112166
Drug: Oral erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral erythromycin ethylsuccinate
Study: 15080578
Drug: Clonidine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.1 mg every 12 hours for 7 days)
Study: 15080578
Drug: Enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5 mg every 12 hours for 7 days)
Study: 9824784
Drug: Cisplatin (CDDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CDDP) 80 mg/m2 by infusion over 2 hours
Study: 9824784
Drug: Cisplatin (CDDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CDDP) 80 mg/m2 by infusion over 3.5 hours
Study: 9824784
Drug: Cisplatin (CDDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CDDP) 80 mg/m2 by infusion over 4 hours
Study: 9824784
Drug: Cisplatin (CDDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CDDP) pharmacodynamics
Study: 9824784
Drug: Cisplatin (CDDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CDDP) pharmacokinetics
Study: 8948268
Drug: L-thyroxine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-thyroxine (100 micrograms/day)
Study: 16394754
Drug: Dynamic extensor
Normalized name: Wolfiporia extensa whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic extensor brace treatment for 12 weeks (Group 1; n = 30)
Study: 16394754
Drug: No brace
Normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No brace treatment (Group 2; n = 33)
Study: 28926170
Drug: Saxagliptin 5
Normalized name: sAXagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin 5 mg plus metformin
Study: 28926170
Drug: Saxagliptin 5
Normalized name: sAXagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin 5 mg plus placebo
Study: 23802840
Drug: Saxagliptin plus
Normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saxagliptin plus metformin
Study: 28406090
Drug: 2 evogliptin/metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 evogliptin/metformin XR 2.5/500 mg FDC tablets
Study: 28406090
Drug: Separate formulations
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate formulations of evogliptin 5 mg and metformin XR 1,000 mg
Study: 23815302
Drug: 2-dose alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-dose alemtuzumab (15 mg at day 0 and 15 mg repeated on day 7)
Study: 16940830
Drug: Once-daily amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily amoxicillin (750 mg or 1000 mg) for 10 days
Study: 16940830
Drug: Twice-daily amoxicillin
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily amoxicillin (2 doses of 375 mg or 500 mg) for 10 days
Study: 16940830
Drug: Once-daily amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily amoxicillin
Study: 15473127
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose sulfonylurea (Glimepiride 8 patients, gliclazide 5 patients)
Study: 15473127
Drug: Repaglinide 2
Normalized name: repaglinide 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide 2 x 2 mg
Study: 11015795
Drug: Trivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent inactivated influenza vaccine (n = 595 in 1997-1998; n = 587 in 1998-1999)
Study: 6547072
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (Adriamycin 25 mg/m2, cyclophosphamide 700 mg/m2, vincristine 1.5 mg/m2, arabinosylcytosine 100 mg/m2, methotrexate 10 mg/m2, prednisone 60 mg/m2) and radiotherapy (2000 rad)
Study: 49984
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy and radiotherapy
Study: 11903513
Drug: Piribedil (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piribedil (3 mg)
Study: 9874055
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of antihypertensive medication
Study: 9874055
Drug: Nonpharmacologic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpharmacologic therapy (weight loss and/or sodium reduction)
Study: 9139386
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg twice daily for 5 days)
Study: 6789354
Drug: Flurazepam 15
Normalized name: flurazepam 15 mg oral capsule
DrugBank: Flurazepam (DB00690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurazepam 15 mg
Study: 29723341
Drug: Pharmacist-led medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led medication counseling session at discharge.
Study: 24563084
Drug: LIS (nutraceutical
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIS (nutraceutical product containing Garcinia cambogia, l-carnitine, and Ascophyllum nodosum)
Study: 20662896
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) 800 mg once daily
Study: 17717534
Drug: HFCS (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFCS (50 g)
Study: 17717534
Drug: Sucromalt (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucromalt (80 g)
Study: 17717534
Drug: HFCS (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFCS (80 g)
Study: 17717534
Drug: Fructose/glucose blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructose/glucose blend (56 g) + inulin (24 g)
Study: 19605831
Drug: Capsule endoscopy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule endoscopy
Study: 10483964
Drug: Oral verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral verapamil (240 mg/day) initiated three days before cardioversion and continued during follow-up (group II)
Study: 8758387
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (MMC) 0.4 mg/ml used in trabeculectomy
Study: 19746201
Drug: Intradetrusor injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradetrusor injections of botulinum toxin‐A (BTX‐A)
Study: 7520188
Drug: Aprotinin (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (140 mg primed in ECC pump, continuous IV perfusion at 70 mg/h)
Study: 26498428
Drug: Constant-current (CC)
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant-current (CC) stimulation
Study: 26498428
Drug: Mixed implants
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed implants (CC after CV replacement)
Study: 30314962
Drug: Treatment-as-usual (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (control group)
Study: 18831859
Drug: Loratadine, 10
Normalized name: Loratadine, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine, 10 mg, once daily
Study: 12146000
Drug: Exemestane 0.5-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane 0.5-50 mg/day after breakfast for 7 days
Study: 1839442
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 mg once daily)
Study: 27797396
Drug: Minocycline 100
Normalized name: minocycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 100 mg
Study: 107450
Drug: Minocycline 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 200 mg
Study: 24093711
Drug: Local tenoxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local tenoxicam injection (1 mL of tenoxicam 20 mg/2 mL and 1 mL of 2% lidocaine)
Study: 24093711
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (1 mL containing 40 mg of methylprednisolone acetate and 1 mL of 2% lidocaine)
Study: 19462320
Drug: Mare's milk
Normalized name: Mare's milk protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mare's milk (250 ml daily for 16 weeks)
Study: 15257848
Drug: Heart disease
Normalized name: BRACELET,MEDICAL ALERT HEART DISEASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heart disease prevention program (12 weekly sessions on lifestyle change and goal setting)
Study: 8031164
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 400 mg of UFT orally for 7 days preoperatively, bolus 20 mg of MMC on the day of operation, bolus 10 mg of MMC the day after operation, followed by 800 mg of FT intravenously for 2 weeks and daily oral administration of 400 mg of UFT thereafter
Study: 8031164
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: Bolus 20 mg of MMC on the day of surgery, bolus 10 mg the day after surgery, and 400 mg of UFT orally daily from 2 weeks after surgery
Study: 3136064
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg tocainide
Study: 21476961
Drug: LDL-C target
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C target of < 100 mg/dl
Study: 21476961
Drug: LDL-C target
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C target of < 130 mg/dl
Study: 27837658
Drug: OLZ (olanzapine
Approvals — FDA: no, EMA: no, PMDA: no
Description: OLZ (olanzapine monotherapy)
Study: 7901248
Drug: Topical diphenylcyclopropenone
Normalized name: Diphenylcyclopropenone
DrugBank: Diphencyprone (DB12173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diphenylcyclopropenone (DPCP)
Study: 3306128
Drug: Intermediate dose
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate dose Methotrexate
Study: 31820537
Drug: Sacubitril/valsartan (97/103
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/valsartan (97/103 mg b.i.d.)
Study: 28553078
Drug: Metformin extended
Normalized name: metFORMIN Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin extended release (XR)
Study: 23046107
Drug: Progestin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestin (5 mg medroxyprogesterone acetate/day for 30 days)
Study: 23046107
Drug: Placebo (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (one pill/day for 30 days)
Study: 20675975
Drug: MS-sNT (morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MS-sNT (morphine sulfate and naltrexone hydrochloride extended release capsules)
Study: 20393176
Drug: Alglucosidase alfa
Normalized name: Alglucosidase Alfa
DrugBank: Alglucosidase alfa (DB01272)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Alglucosidase alfa (20 mg/kg biweekly for 78 weeks)
Study: 16392706
Drug: Rice diet
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice diet (protein, 6.3 g; fat, 0.9 g; CHO, 79.3 g; energy, 368 kcal)
Study: 16392706
Drug: Bread diet
Normalized name: Eazi-Breed CIDR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bread diet (protein, 15.7 g; fat, 5.8 g; CHO, 79.2 g; energy, 450 kcal)
Study: 2853961
Drug: terfenadine 60
Normalized name: terfenadine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: terfenadine 60 mg orally
Study: 2853961
Drug: enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril 5 mg orally 3 h before
Study: 29883070
Drug: Insulin alone
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin alone (CONT group; n = 20)
Study: 30618475
Drug: Cariprazine (1.5-4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariprazine (1.5-4.5 mg/day)
Study: 1090417
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate cream
Study: 11549974
Drug: rizatriptan 10‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: rizatriptan 10‐mg wafer
Study: 2906290
Drug: Oral yohimbine
Normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral yohimbine (0.2 mg kg-1)
Study: 19930765
Drug: Berry purée
Normalized name: PEA PUREE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berry purée with 35 g sucrose
Study: 15933563
Drug: Amoxicillin/clavulanate (90/6.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (90/6.4 mg/kg/d in 2 divided doses for 10 days)
Study: 15933563
Drug: Azithromycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (10 mg/kg for 1 day followed by 5 mg/kg/d for 4 days)
Study: 10747531
Drug: Control (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (blood pressure, weight, and pulse measured at six weekly intervals)
Study: 2096499
Drug: Chloroquine 25
Normalized name: chloroquine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine 25 mg/kg body weight over 3 days
Study: 2096499
Drug: Mefloquine 25
Normalized name: mefloquine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine 25 mg/kg body weight single dose
Study: 30337172
Drug: Inactivated monovalent
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated monovalent influenza A/H1N1 vaccine (IIV), two doses administered three weeks apart
Study: 10590183
Drug: Heparin-treated patients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-treated patients
Study: 8168235
Drug: pyquiton at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: pyquiton at a single dose of 2.5 mg/kg
Study: 8168235
Drug: pyquiton (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: pyquiton (not specified dosage)
Study: 3021082
Drug: Concomitant administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant administration of naloxone hydrochloride and yohimbine hydrochloride
Study: 22270205
Drug: All BTXA
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All BTXA preparations combined
Study: 11396535
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (RBC) 400 mg b.d. plus amoxycillin 1 g b.d. and clarithromycin 500 mg b.d. for 7 days
Study: 11396535
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (RBC) 400 mg b.d. plus amoxycillin 1 g b.d. and clarithromycin 500 mg b.d. for 7 days followed by 3 weeks of RBC 400 mg b.d. alone
Study: 9935258
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg alatrofloxacin daily followed by 200 mg oral trovafloxacin daily
Study: 11039067
Drug: 0.4% SnF2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4% SnF2 gel with 98% available Sn2+ ion, used twice daily for nine months
Study: 347857
Drug: Combined oestrogen/androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oestrogen/androgen compound
Study: 28091532
Drug: Ibudilast (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibudilast (50 mg b.i.d.)
Study: 26987135
Drug: Metoprolol succinate
Normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol succinate (59.1 ± 12.1 mg/d)
Study: 29222619
Drug: Behavioural sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural sleep medicine (BSM) intervention targeting physical activity and eating behaviour (10 individual sessions with a dietician and a physiotherapist).
Study: 29222619
Drug: Behavioural sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural sleep medicine (BSM) intervention targeting physical activity and eating behaviour.
Study: 17142063
Drug: Acetaminophen ER
Normalized name: acetaminophen Extended Release Oral Tablet
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen ER 1950 mg
Study: 9710686
Drug: 0.1/0.06 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1/0.06 mg/kg r-hirudin (bolus/infusion per hour over 48 h)
Study: 9710686
Drug: 0.2/0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2/0.1 mg/kg r-hirudin (bolus/infusion per hour over 48 h)
Study: 9710686
Drug: 0.4/0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4/0.15 mg/kg r-hirudin (bolus/infusion per hour over 48 h)
Study: 7859799
Drug: All dosage
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All dosage groups
Study: 19368788
Drug: 0.1mL intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1mL intradermal influenza vaccine
Study: 11504318
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (nortriptyline)
Study: 9133547
Drug: Trimethaphan (0.3-0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethaphan (0.3-0.6 mg/min)
Study: 9133547
Drug: Regular human
Normalized name: insulin regular human recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular human insulin (0.28 pmol x m(-2) x min(-1)) with variable rate glucose infusion
Study: 29420073
Drug: 380 mg
Normalized name: aspirin 380 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 380 mg intramuscular injections of long‐acting naltrexone on study day 1 and at the start of study week 5
Study: 21674691
Drug: Sequential finger
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential finger tapping task
Study: 19413822
Drug: Nasal cannula
Normalized name: EUCALYPTUS OIL 0.15 g in 1 g / MENTHOL, UNSPECIFIED FORM 0.2 g in 1 g / ARGININE 0.1 g in 1 g TOPICAL CREAM [Slimming Detox Nasal Cannula]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal cannula oxygen administration at 2 l x min(‐1)
Study: 19413822
Drug: Nasal cannula
Normalized name: EUCALYPTUS OIL 0.15 g in 1 g / MENTHOL, UNSPECIFIED FORM 0.2 g in 1 g / ARGININE 0.1 g in 1 g TOPICAL CREAM [Slimming Detox Nasal Cannula]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal cannula oxygen administration at 4 l x min(‐1)
Study: 19413822
Drug: Nasal cannula
Normalized name: EUCALYPTUS OIL 0.15 g in 1 g / MENTHOL, UNSPECIFIED FORM 0.2 g in 1 g / ARGININE 0.1 g in 1 g TOPICAL CREAM [Slimming Detox Nasal Cannula]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal cannula oxygen administration at all flow rates
Study: 12100641
Drug: Manual pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual pressure applied before intramuscular injection for 10 seconds
Study: 12100641
Drug: Conventional injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional injection without manual pressure
Study: 7883836
Drug: Alprazolam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (2 mg, orally)
Study: 7968328
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg sublingual)
Study: 16446685
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein (40 g protein/day)
Study: 16446685
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (40 g protein/day)
Study: 14609102
Drug: Pimecrolimus 1%
Normalized name: PIMECROLIMUS 1% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimecrolimus 1% ointment applied twice daily for 21 days
Study: 14609102
Drug: Vehicle (corresponding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (corresponding vehicle ointment)
Study: 8915143
Drug: Calcipotriol 0.005%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol 0.005% ointment
Study: 14609102
Drug: Clobetasol-17-propionate 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobetasol-17-propionate 0.05% ointment
Study: 2671283
Drug: CMFVP (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMFVP (combination cyclophosphamide 60 mg/m2 orally every day for 1 year; fluorouracil 300 mg/m2 IV weekly for 1 year; methotrexate 15 mg/m2 IV weekly for 1 year; vincristine 0.625 mg/m2 IV for 10 weeks; prednisone 30 mg/m2 orally days 1 to 14, 20 mg/m2 days 15 to 28, 10 mg/m2 days 29 to 42)
Study: 339787
Drug: fenoterol (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenoterol (0.4 mg t.i.d. or q.i.d.)
Study: 339787
Drug: isoproterenol (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: isoproterenol (0.15 mg t.i.d. or q.i.d.)
Study: 31833059
Drug: 24-hour maintenance
Normalized name: cenobamate
DrugBank: Cenobamate (DB06119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 24-hour maintenance dose of magnesium sulfate (MgSO4)
Study: 22065870
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group DMP includes individualized education and follow-up from a multidisciplinary heart failure team; a weekly education programme for 12 weeks; self-management advice; and medical follow-up.
Study: 18805773
Drug: Diclofenac-orphenadrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac-orphenadrine infusion (Group A)
Study: 16599097
Drug: SuperSeal (oxalate
Approvals — FDA: no, EMA: no, PMDA: no
Description: SuperSeal (oxalate preparation)
Study: 8403157
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (0.5 mg.kg‐1) premedication, 10 min interval
Study: 8403157
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (0.5 mg.kg‐1) premedication, 20 min interval
Study: 8403157
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (0.5 mg.kg‐1) premedication, 30 min interval
Study: 26818228
Drug: Cholecalciferol 4000
Normalized name: Cholecalciferol 4000 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 4000 International Units daily for 16 weeks
Study: 26818228
Drug: Cholecalciferol 2000
Normalized name: cholecalciferol 2000 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 2000 International Units daily for 16 weeks
Study: 22735040
Drug: Financial incentive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Financial incentive version of smoking cessation treatment costing $750 per success